56
Participants
Start Date
September 28, 2023
Primary Completion Date
May 14, 2025
Study Completion Date
May 14, 2027
FCN-159
5mg/m² (Maximum dose does not exceed 8mg, the recommended oral dose for adults), orally, once daily, continuously for 28 days per cycle.
RECRUITING
Beijing Children's Hospital, Capital Medical University, Beijing
NOT_YET_RECRUITING
Children's Hospital Affiliated to the Capital Institute of Pediatrics, Beijing
RECRUITING
Children's Hospital of Chongqing Medical University, Chongqing
NOT_YET_RECRUITING
Sun Yat-Sen Memorial Hpsipital,Sun Yat-Sen Unniversity, Guangzhou
NOT_YET_RECRUITING
The First Affiliated Hospital,Sun Yat-sen University, Guangzhou
NOT_YET_RECRUITING
Shenzhen Children's Hospital, Shenzhen
NOT_YET_RECRUITING
Henan Children's Hospital Zhengzhou Children's Hospital, Zhengzhou
NOT_YET_RECRUITING
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan
NOT_YET_RECRUITING
West China Second University Hospital,Sihuan University/West China women's and Children's Hospital, Chengdu
NOT_YET_RECRUITING
Children's Hospital, Zhejiang University School of Medicine, Hangzhou
NOT_YET_RECRUITING
Children's Hospital of Soochow University, Suzhou
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
INDUSTRY